cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Neuroblastoma
Inhibiton Therapeutics Announces ICA-1 Compound Effective in In-Vitro Testing in Various Cancer Cell Lines
December 18th, 2007
Inhibiton Therapeutics, Inc. (OTC/BB: IHBT) announced that its ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines. The present work performed under a Co-operative Research and Development Agreement (CRADA) with the Department of Veteran's Affairs (VA) demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy. Laboratory testing to date has shown that ICA-1 was effective in blocking BE(2)C neuroblastoma cells. It was also found that lower concentrations of ICA-1 were more efficacious in inhibiting the proliferation of 64%...
Source: cancer weekly (2007-12-18)
|
